Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu ReddyLindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journalReview article

27 Scopus citations


Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Original languageEnglish (US)
Pages (from-to)1193-1207
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number10
StatePublished - Oct 1 2017


ASJC Scopus subject areas

  • Oncology

Cite this

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., McMahon, B., Mohan, S. R., Oh, S., Padron, E., Papadantonakis, N., Pancari, P., Podoltsev, N., Rampal, R., Ranheim, E., ... Sundar, H. (2017). Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(10), 1193-1207.